Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Regeneron Pharmaceuticals, Inc. (REGN) stock forecast summary
On Oct. 16, 2026, REGN is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5171 stocks scored that day.
Regeneron Pharmaceuticals, Inc. is a large-cap company with a market capitalization of $82.34B. It ranks number 14 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its Dividend Yield of 0.46% is the lowest of the 10 peers that report one.
For REGN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 24.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 7.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, REGN included.
Follow REGN freeREGN price chart and AI forecast
How REGN ranks among 5171 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Regeneron Pharmaceuticals, Inc. (REGN) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | REGN | Rank |
|---|---|---|
| Market Cap | $82.34B | 14/60 |
| P/E Ratio | 19.72x | 20/32 |
| P/B Ratio | 2.60x | 39/42 |
| Dividend Yield | 0.46% | 10/10 |
| EPS | $40.38 | – |
| Book Value/Share | $306.69 | – |
| Revenue/Share | $150.24 | – |
| FCF/Share | $36.37 | – |
Profitability & Margins
| Metric | REGN | Rank |
|---|---|---|
| ROIC | 10.6% | 14/46 |
| Operating Margin | 50.7% | 3/39 |
| EBT Margin | 68.1% | 3/46 |
| Tax Rate | 16.2% | – |
Financial Health
| Metric | REGN | Rank |
|---|---|---|
| Current Ratio | 3.34x | 27/59 |
| Quick Ratio | 2.78x | 14/43 |
| D/E Ratio | 0.32x | 34/48 |
| Financial Leverage | 1.32x | 33/48 |
| Interest Coverage | 21.1x | 8/36 |
| Working Capital | $12.92B | 2/59 |
Cash Flow
| Metric | REGN | Rank |
|---|---|---|
| Operating Cash Flow | $4.68B | 14/59 |
| Free Cash Flow | $3.76B | 13/50 |
| Capital Spending | -$921M | 39/50 |
| OCF Growth YoY | -1.3% | 21/33 |
| FCF Growth YoY | -2.4% | 24/31 |
| FCF/Sales | 24.2% | 11/42 |
| CapEx/Sales | 5.9% | 8/42 |
Operational Efficiency
| Metric | REGN | Rank |
|---|---|---|
| Asset Turnover | 0.37x | 29/40 |
| Receivables Turnover | 2.4x | 35/37 |
| Fixed Assets Turnover | 2.9x | 32/41 |
| Days Sales Outstanding | 154 days | 3/37 |
Income Statement
| Metric | REGN | Rank |
|---|---|---|
| Total Revenue | $15.53B | 12/46 |
| Operating Income | $3.84B | 10/51 |
| R&D Expense | $6.28B | 12/58 |
| SG&A Expense | $2.74B | 14/40 |
Dividend & Shareholder Information
| Metric | REGN | Rank |
|---|---|---|
| Dividends Per Share | $3.66 | – |
| Payout Ratio | 9.1% | 10/10 |
| Shares Outstanding | 103M | – |
| EPS Growth | 1.6% | 12/24 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $18.45B | 44.2% of assets |
| Cash & Short-term Investments | $2.46B | 5.9% of assets |
| Accounts Receivable | $6.57B | 15.7% of assets |
| Inventory | $3.08B | 7.4% of assets |
| Total Liabilities | $10.02B | 24.0% of assets |
| Short-term Debt | $4.37B | 10.5% of assets |
REGN quarterly financials and insider trading
Regeneron Pharmaceuticals, Inc. (REGN) industry peers
Companies classified under the same SEC industry code as Regeneron Pharmaceuticals, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | ▶ | $82.34B |
| LLY Eli Lilly & Co | ▶ | $1.18T |
| JNJ Johnson & Johnson | ▼ | $615.87B |
| ABBV Abbvie Inc. | ▶ | $504.46B |
| MRK Merck & Co., Inc. | ▲ | $360.08B |
| NVS Novartis Ag | ▼ | $286.95B |
| AZN Astrazeneca Plc | ▼ | $256.39B |
| ABT Abbott Laboratories | ▼ | $182.37B |
| NVO Novo Nordisk A S | ▼ | $174.29B |
| PFE Pfizer Inc | ▶ | $167.80B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▶ | $128.95B |
| BMY Bristol Myers Squibb Co | ▶ | $122.05B |
| GSK Gsk Plc | ▼ | $100.46B |
| SNY Sanofi | ▼ | $99.33B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $60.76B |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $47.91B |
| ONC Beone Medicines Ltd. | ▲ | $42.53B |
| ZTS Zoetis Inc. | ▼ | $32.40B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $31.02B |
| RPRX Royalty Pharma Plc | ▶ | $26.29B |
| ROIV Roivant Sciences Ltd. | ▲ | $24.59B |
| GMAB Genmab A/S | ▲ | $23.80B |
| UTHR United Therapeutics Corp | ▶ | $23.23B |
| INSM Insmed Inc | ▶ | $21.02B |
| VTRS Viatris Inc | ▼ | $20.93B |
| ASND Ascendis Pharma A/S | ▲ | $14.85B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.65B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.98B |
| SMMT Summit Therapeutics Inc. | ▶ | $12.26B |
| CORT Corcept Therapeutics Inc | ▲ | $11.91B |
| ELAN Elanco Animal Health Inc | ▼ | $11.77B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.77B |
| BMRN Biomarin Pharmaceutical Inc | ▶ | $10.58B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.39B |
| TGTX Tg Therapeutics, Inc. | ▲ | $8.89B |
| PTGX Protagonist Therapeutics, Inc | ▶ | $8.84B |
| CYTK Cytokinetics Inc | ▲ | $8.61B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.23B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $7.90B |
| ABVX Abivax S.A. | ▼ | $7.74B |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.14B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.06B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.93B |
| ALKS Alkermes Plc. | ▲ | $6.92B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▶ | $6.13B |
| AMRX Amneal Pharmaceuticals, Inc. | ▲ | $6.13B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▲ | $6.06B |
| LGND Ligand Pharmaceuticals Inc | ▶ | $5.89B |
| BLTE Belite Bio, Inc | ▲ | $5.62B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.35B |
| COGT Cogent Biosciences, Inc. | ▶ | $5.12B |
| PTCT Ptc Therapeutics, Inc. | ▲ | $5.09B |
| ORKA Oruka Therapeutics, Inc. | ▲ | $4.89B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.72B |
| ERAS Erasca, Inc. | ▲ | $4.68B |
| MANE Veradermics, Inc | ▲ | $4.55B |
| EWTX Edgewise Therapeutics, Inc. | ▲ | $4.04B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.03B |
| INDV Indivior Pharmaceuticals, Inc. | ▶ | $3.83B |
| TNGX Tango Therapeutics, Inc. | ▲ | $3.83B |
Where REGN sits on the market map
Regeneron Pharmaceuticals, Inc. (REGN) stock news
Loading...
Regeneron Pharmaceuticals, Inc. (REGN) stock forecast FAQ
What is the Regeneron Pharmaceuticals, Inc. (REGN) stock forecast?
On Oct. 16, 2026, REGN is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5171 stocks scored that day.
How accurate are Regeneron Pharmaceuticals, Inc. stock predictions?
For REGN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 24.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 7.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Regeneron Pharmaceuticals, Inc. forecasts updated?
Regeneron Pharmaceuticals, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Regeneron Pharmaceuticals, Inc.'s industry peers?
60 issuers in our coverage, REGN included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.